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OBJECTIVE—Elevated plasma triglyceride concentration is a
component of the insulin resistance syndrome and is commonly
associated with type 2 diabetes, obesity, and coronary heart
disease. The goal of our study was to perform a genome-wide
linkage scan to identify genetic regions that inﬂuence variation in
plasma triglyceride levels in families that are enriched with
individuals with type 2 diabetes.
RESEARCH DESIGN AND METHODS—We used phenotypic
and genotypic data from 1,026 individuals distributed across 294
Mexican-American families, who were ascertained for type 2
diabetes, from the Veterans Administration Genetic Epidemiol-
ogy Study (VAGES). Plasma triglyceride values were trans-
formed, and a variance-components technique was used to
conduct multipoint linkage analysis.
RESULTS—After adjusting for the signiﬁcant effects of sex and
BMI, heritability for plasma triglycerides was estimated as 46 
7% (P  0.0001). Multipoint linkage analysis yielded the strongest
evidence for linkage of plasma triglycerides near marker
D12S391 on chromosome 12p (logarithm of odds [LOD]  2.4).
Our linkage signal on chromosome 12p provides independent
replication of a similar ﬁnding in another Mexican-American
sample from the San Antonio Family Diabetes Study (SAFDS).
Combined multipoint linkage analysis of the VAGES and SAFDS
data yielded signiﬁcant evidence for linkage of plasma triglycer-
ides to a genetic location between markers GATA49D12 and
D12S391 on 12p (LOD  3.8, empirical P value  2.0  10
5).
This region on 12p harbors the gene-encoding adiponectin recep-
t o r2( AdipoR2), where we previously have shown that multiple
single nucleotide polymorphisms are associated with plasma
triglyceride concentrations in the SAFDS. In the present study,
we provided suggestive evidence in favor of association for
rs929434 with triglyceride concentrations in the VAGES.
CONCLUSIONS—Collectively, these results provide strong ev-
idence for a major locus on chromosome 12p that inﬂuences
plasma triglyceride levels in Mexican Americans. Diabetes 58:
279–284, 2009
T
he insulin resistance (metabolic) syndrome is
characterized by an increase in plasma triglycer-
ide concentration, reduced HDL, visceral obe-
sity, elevated blood pressure, and glucose
intolerance (1,2). The prevalence of the insulin resistance
syndrome and/or related diseases, including obesity and
type 2 diabetes, is rapidly increasing. Although major risk
factors for these disorders have been identiﬁed, the ge-
netic factors remain largely unknown. Elevated plasma
triglyceride concentration is a component of the insulin
resistance syndrome and is commonly associated with
type 2 diabetes, obesity, and coronary heart disease (1,2).
Since knowledge of speciﬁc genetic determinants of the
common forms of hypertriglyceridemia is limited, we
conducted a genome-wide linkage scan to localize genes
that inﬂuence variation in plasma triglyceride levels in
Mexican-American families ascertained for type 2 diabetes
from the Veterans Administration Genetic Epidemiology
Study (VAGES).
Genome-wide linkage screens for plasma triglyceride
levels have been performed in several populations, includ-
ing our previous study in Mexican Americans from the San
Antonio Family Diabetes Study (SAFDS) (3,4). In that
study, we reported signiﬁcant evidence for the linkage of
triglycerides to a genetic location on chromosome 15q and
found potential evidence for linkage on several chromo-
somal regions including 12p (3,4). Linkage to chromo-
somes 2p, 11p, and 11q also have been reported for plasma
triglyceride levels in French-Canadian families from the
Quebec Family Study (5). In addition, a study performed in
families with northern European ancestry demonstrated
evidence for linkage to plasma triglyceride levels on
chromosome 19 (6). Additionally, a study in a Chinese
population from the Hong Kong Family Diabetes Study
identiﬁed several chromosomes, including 2q, 3q, 6q, 9q,
10q, and 17q, containing genes that inﬂuence variation in
triglyceride levels (7). Other evidence for the linkage of
plasma triglyceride levels has been reported on 8q in
African Americans (8), 2q in Hutterites (9), 11q in Old
Order Amish (10), and 10p in Finnish families (11). More
recently, a meta-analysis of genome-wide linkage studies
for plasma triglyceride levels provided suggestive evi-
dence for linkage at chromosome 7p (12). The purpose of
this study was to perform a genome-wide linkage scan to
identify genetic regions that inﬂuence variation in plasma
triglyceride levels in Mexican-American individuals from
VAGES, in which the families were ascertained for type 2
diabetes.
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VAGES. The study participants for whom both genetic and phenotypic data
were available consisted of 1,026 Mexican Americans distributed across 294
mostly nuclear families from VAGES. Of 294 families, however, 41 were found
to be represented by single individuals with triglyceride data. These 41 single,
unrelated individuals were considered for the analysis because they contrib-
ute to the evaluation of covariate effects. The remaining 985 individuals from
253 families generated 1,715 relative pairs that were distributed across nine
relative-pair categories (Table 1). The VAGES families were ascertained on at
least two siblings affected with type 2 diabetes and only one parent with type
2 diabetes. Metabolic, anthropometric, demographic, and medical history
information were obtained on all examined individuals. All procedures were
approved by the institutional review board of the University of Texas Health
Science Centre at San Antonio, and all subjects gave informed written consent
before their participation.
Blood samples were obtained after a 12-h fast. Plasma triglyceride concen-
trations were determined by an enzymatic colorimetric quantiﬁcation method
(Wako Chemicals, Nuess, Germany). After excluding three extreme outliers,
plasma triglyceride values were available for 1,023 individuals and were used
to conduct the present study, and no values 1 SD from the next lowest value
were included. To address the issue of continued nonnormality, plasma
triglyceride values were transformed using an inverse-normal transformation.
Genotype data, genetic map, and estimation of identity-by-descent
matrices. DNA was prepared from whole blood (Gentra Systems, Minneap-
olis, MN). The Center for Inherited Disease Research (CIDR) performed a
10-cM genome scan using the DNA samples from the VAGES participants. We
used CIDR genotypic data on 385 highly polymorphic autosomal markers. The
program PREST (13) was used to resolve pedigree discrepancies. The
genotype data were cleaned for both Mendelian inconsistencies and spurious
double recombinants using the program SimWalk2 (14,15). Overall, the
blanking rate for errors was 0.22% of the total number of genotypes. The
PEDSYS (16) program INFER was used to infer unknown genotypes from
the genotypes of relatives, when possible without ambiguity. The genetic
maps used for the present analyses were similar to the Marshﬁeld maps. The
multipoint identical-by-descent (IBD) matrices given a number of genetic
markers (map distance in Haldane cM) were calculated using Markov chain
Monte Carlo methods implemented in the program Loki (17,18).
Variance-components linkage analysis. We used a pedigree-based multi-
point variance-components approach to test for linkage between genetic
locations and the transformed triglyceride levels using maximum-likelihood
methods (19–21). The variance-components method uses information from all
possible biological relationships simultaneously to disentangle the genetic
architecture of the quantitative trait. This method speciﬁes the expected
genetic covariances between relatives as a function of their IBD relationships
at a marker locus (which is hypothesized to be linked to a locus inﬂuencing
the quantitative trait [QTL]). It allows for locus-speciﬁc effects (h
2
q is
heritability attributed to the QTL), residual additive genetic effects (h
2 is
heritability attributed to the residual genetic effects), and individual-speciﬁc
random environmental factors [e
2  1  (h
2
q  h
2)].
In addition to the variance components, mean  SD of the phenotype and
covariate effects (e.g., age and BMI) were simultaneously estimated by
maximum-likelihood techniques. Hypothesis testing was performed by likeli-
hood ratio tests. The hypothesis of no linkage (i.e., additive genetic variance
due to the QTL  0) was tested by comparing the likelihood of this restricted
model with that of a model in which the additive genetic variance due to the
QTL is estimated. The difference between the two log10 likelihoods produces
a logarithm of odds (LOD) score. Twice the difference in the loge likelihoods
of these models yields a test statistic that is asymptotically distributed as the
1⁄2:1⁄2 mixture of 
2
1 and a point mass at 0, denoted by 
2
0, where the degree of
freedom is equal to the difference in the number of parameters estimated
between the two competing models (22). An LOD score of 3.0 was
considered as strong evidence in support of linkage. For the purpose of
discussion, other genetic regions across the genome with LOD scores 1.2
and 1.9 are considered evidence for potential linkage and suggestive linkage,
respectively. Given the initial set of covariates of transformed triglyceride
levels considered for an analysis, the program SOLAR was used to evaluate
the statistical signiﬁcance (P  0.05) of a given covariate using likelihood ratio
tests. Each of these tests involved comparison for a given parameter and had
one degree of freedom. Given the VAGES family ascertainment criteria, all of
our genetic analyses incorporated correction for ascertainment bias by
computing the likelihood of a pedigree conditional on the transformed
triglyceride value of the proband, using the program SOLAR. Since the VAGES
families had more than one proband per family, we randomly chose one of the
probands from each family to correct for ascertainment bias since correcting
TABLE 1
Distribution of relative pairs by category in the VAGES and SAFDS families
Relative pair
Relationship
coefﬁcient*
Number of VAGES
pairs†
Number of SAFDS
pairs‡
Parent-offspring 0.5 416 463
Siblings 0.5 1,003 586
Grandparent-grandchild 0.25 19 123
Avuncular 0.25 184 810
Half-siblings 0.25 47 88
First and second cousins 0.15625 — 20
Double ﬁrst cousins 0.25 — 10
Great grandparent-grandchild 0.125 — 12
Grand avuncular 0.125 6 204
Half-avuncular 0.125 15 106
First cousins 0.125 24 793
Double ﬁrst cousins, once removed 0.125 — 35
First and second cousins, once removed 0.078125 — 22
Great grand avuncular 0.0625 — 2
Half grand avuncular 0.0625 — 5
First cousins, once removed 0.0625 1 759
Half ﬁrst cousins 0.0625 — 77
Double second cousins 0.0625 — 25
Second and third cousins 0.0390625 — 6
First cousins, twice removed 0.03125 — 30
Half ﬁrst cousins, once removed 0.03125 — 13
Second cousins 0.03125 — 287
Second cousins, once removed 0.015625 — 75
Third cousins 0.0078125 — 8
Total 1,715 4,559
*The relationship coefﬁcient is 2  coefﬁcient of kinship of two individuals. †The total data used for the present study were obtained from
1,026 individuals distributed across 294 families. Of 1,026, however, 41 were unrelated individuals (see text for details). ‡The total data used
for the present study were obtained from 537 individuals distributed across 31 families.
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can result in a loss of power to detect linkage (23,24). We performed
simulation analysis to determine the empirical P value to verify our major
linkage ﬁnding. A fully informative marker, not linked to triglyceride, was
simulated, IBD information for this simulated marker was calculated, and
linkage analysis was performed. The empirical P value was determined based
on information obtained from 100,000 replicates. The statistical genetic
analytical procedures were implemented in the SOLAR program.
Single nucleotide polymorphism genotyping and association analysis.
We typed rs929434 in AdipoR2 in the VAGES data to perform association
analysis with triglyceride concentrations using methods described previously
(4). DNA samples for genotyping were available for 907 individuals only.
SAFDS. The goals and related genetic investigations of SAFDS have been
extensively described previously (25–27). Brieﬂy, probands for SAFDS were
individuals with type 2 diabetes, and all of the probands’ ﬁrst-, second-, and
third-degree relatives aged 18 years were invited to participate in the study.
Type 2 diabetes–related phenotypes were collected, and a 10-cM genome scan
was performed by CIDR. The SAFDS baseline data used for this study were
reported in Table 2, and 537 individuals from 31 complex, multigenerational
families generated 4,559 relative pairs that were distributed across 24 relative-
pair categories (Table 1).
RESULTS
The characteristics of the VAGES participants are re-
ported in Table 2. After accounting for the signiﬁcant
covariate effects of sex and log-transformed BMI (ln BMI),
the overall polygenic heritability (h
2) for transformed
plasma triglyceride values was estimated to be 46  7%,
with high statistical signiﬁcance (P  0.0001). It should be
noted that normality was maintained approximately, after
adjustment for covariate inﬂuences (i.e., the skewness and
kurtosis coefﬁcients of the residuals is 0.01 and 0.11,
respectively). The initial set of covariates considered for
evaluation of statistical signiﬁcance included sex, age,
age
2, age  sex, age
2  sex, and ln BMI. Following the
determination of the heritability for triglycerides, the
multipoint linkage analysis was conducted, and the results
of our genome-wide linkage screen (i.e., peak LOD score
by chromosome) are summarized in Fig. 1.
The strongest evidence for linkage (LOD  2.4) of
triglycerides occurred on chromosome 12 at 	26 cM near
marker D12S391. The multipoint LOD scores obtained for
transformed plasma triglyceride were plotted against map
positions on chromosome 12 (Fig. 2). In addition to the
evidence for suggestive triglyceride linkage on chromo-
some 12 near marker D12S391, four other regions on four
TABLE 2
Characteristics of VAGES and SAFDS participants for whom
both phenotypic and genotypic data were available
Variable VAGES SAFDS
n 1,026 537
Age at examination (years) 49.6  13.1 42.1  16.8
Female subjects (%) 65.9 58.3
Diabetic subjects (%) 68.6 24.6
BMI (kg/m
2) 33.2  8.0 30.2  6.6
ln BMI* 3.5  0.2 3.4  0.2
Plasma triglycerides (mg/dl)† 159  136 180  135
Data are means  SD or percent. *ln  log transformed. †Plasma
triglyceride values were transformed for the genetic analysis using
inverse normal transformation.
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FIG. 1. Summary of the genome-wide linkage scan for genes inﬂuencing (transformed) plasma triglyceride levels in VAGES.
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linkage, with LOD scores 1.2 (Table 3).
Our linkage on chromosome 12p provides an indepen-
dent replication of a similar ﬁnding in other Mexican-
American data obtained from the SAFDS (3,4). Given that
SAFDS has a new genome scan performed by CIDR (26),
we reanalyzed the SAFDS data (3) but included all of the
available triglyceride information (n  537 compared with
the initial linkage data based on a sample of 418 individ-
uals) (Table 2) and the new (CIDR) chromosome 12
marker data. As in the case of VAGES, the plasma triglyc-
eride values in SAFDS were transformed using the inverse-
normal transformation and the analysis incorporated
correction for the ascertainment bias given the SAFDS
ascertainment scheme (3). After adjusting for the signiﬁ-
cant covariate effects of age, sex, age  sex, age
2, and ln
BMI on triglycerides, the reanalysis (the skewness and
kurtosis values for residuals were 0.08 and 0.04, respec-
tively) yielded potential evidence for linkage (LOD  1.5)
at 	17 cM near marker GATA49D12. Following this, we
performed a combined VAGES and SAFDS plasma triglyc-
eride linkage analysis using a combined chromosome 12
map and study-speciﬁc multipoint IBD matrices. After
accounting for the above-said covariates and study as an
additional covariate (the skewness and kurtosis coefﬁ-
cients for residuals were 0.07 and 0.02, respectively), the
combined multipoint linkage analysis yielded signiﬁcant
evidence for linkage of transformed plasma triglycerides
(LOD  3.8, empirical P value  2.0  10
5) to a genetic
location at 	 24 cM between markers GATA49D12 (17 cM)
and D12S391 (26 cM) on chromosome 12p (Fig. 2). The
empirical P value that corresponds to our observed LOD
score is similar to our nominal P value, which suggests
that our nominal P value has not overstated the evidence
of linkage.
As part of the present study, we genotyped (n  907) the
most strongly associated single nucleotide polymorphisms
(SNPs) (rs929434) with triglycerides observed in the
SAFDS (P  0.00016) (4), in the VAGES data and found
suggestive evidence in favor of association (P  0.06505).
The rare allele was associated with decreased triglyceride
concentrations in both the SAFDS and VAGES datasets.
We obtained the combined P value (0.00013) using Fisher’s
combined P value approach, in turn ﬁnding a slight im-
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FIG. 2. Multipoint linkage results for (transformed) plasma triglyceride levels at the chromosome 12 region in the VAGES, SAFDS, and combined
VAGES and SAFDS datasets.
TABLE 3
Chromosomal regions potentially linked (LOD 1.2) to (trans-
formed) plasma triglyceride levels
Nearest marker
Distance
(cM)*
Chromosome
location LOD
D2S434 216 2q 1.3
D6S1027 187 6q 2.2
D10S1656 149 10q 1.2
D20S477 47 20p 1.5
*Marshﬁeld data.
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VAGES data, however, the observed suggestive associa-
tion explains only a small portion (	5%) of the initial
linkage signal.
DISCUSSION
In this study, we report the results from a genome-wide
linkage scan undertaken in VAGES to identify genes that
inﬂuence variation in plasma triglyceride levels. We found
that plasma triglyceride levels were suggestively linked to
a genetic location near marker D12S391 on chromosome
12. Potential evidence for linkage also was observed on
chromosomes 2q, 6q, 10q, and 20p. The linkage on chro-
mosome 12 was an independent replication of our previ-
ously (or presently) reported triglyceride linkage ﬁnding in
Mexican Americans from SAFDS, where we found modest
evidence for linkage of plasma triglyceride levels at 12p
(3,4). Our combined linkage analysis of VAGES and
SAFDS increased our power to detect statistically signiﬁ-
cant evidence for linkage at 12p (LOD  3.8, empirical P
value  2.0  10
5). Taken together, these results provide
strong evidence for a major susceptibility locus on 12p
that inﬂuences plasma triglyceride levels in Mexican
Americans.
Other genome-wide linkage screens in different popula-
tions reported evidence of linkage for plasma triglyceride
levels on chromosomes 2p, 2q, 3q, 6q, 8q, 9q, 10p, 10q, 11p,
11q, 17q, and 19q (5–11). With the exception of 2q, 6q, and
10q, the majority of these loci appear to have no strong
effects in the Mexican Americans. Consistent with our
ﬁndings, a genome-wide linkage scan of plasma triglycer-
ide concentrations in the Framingham Heart Study identi-
ﬁed modest evidence for linkage on 12p (28). In contrast,
the linkage of 12p to plasma triglyceride levels has not
been replicated in the studies mentioned above (5–11),
including a meta-analysis of genome-wide linkage studies
for plasma triglyceride levels (12). This lack of replication
is not surprising and may arise due to factors such as
different study designs, sample size, choice or power of the
statistical methods used, and genuine genetic heterogene-
ity. In addition, replication of a true linkage in a phenotype
with complex inheritance patterns (e.g., oligogenic inher-
itance) appears to be difﬁcult since it is likely to require a
larger number of families than is required for initial
detection (29). As can be seen from our present study,
however, the combined VAGES and SAFDS linkage anal-
ysis provided stronger evidence for linkage of triglyceride
levels on chromosome 12p compared with the indepen-
dent linkage information provided by VAGES and SAFDS
separately. In addition to these genome-wide linkage ﬁnd-
ings, more recently, genome-wide association studies have
also identiﬁed additional loci/SNPs associated with triglyc-
eride levels including GCKR, LPL, APOA5, and TRIB1
(30–33). These reported loci/SNPs do not overlap with the
chromosomal regions that we have identiﬁed in the
present study.
Many genes that could plausibly play a role in the
regulation of plasma triglyceride levels reside within the
critical linkage region at 12p. One of these positional
candidate genes is adiponectin receptor 2 (AdipoR2,
12p13.33). AdipoR2 is one of two receptors that mediate
the effects of adiponectin, an important regulator of en-
ergy homeostasis and glucose and lipid metabolism (34).
As we reported previously (4), multiple SNPs in AdipoR2
were signiﬁcantly associated with decreased plasma tri-
glyceride levels (4). In this same study, we demonstrated
that one of these SNPs (rs929434) accounted for 47% of the
linkage in the previously reported genome-wide linkage
scan performed in a subset of SAFDS (3). In the present
study, we found suggestive evidence in favor of associa-
tion with rs929434 (P  0.06505) in VAGES, and the
observed suggestive association explains only a small
portion (	5%) of the initial linkage signal. Following these
ﬁndings, we have started typing a large battery of SNPs in
AdipoR2 to further conﬁrm the association between ge-
netic variation in AdipoR2 and triglyceride levels.
In addition to our own ﬁndings, several other groups
have reported that polymorphisms in AdipoR2 are associ-
ated with type 2 diabetes, obesity, and other components
of the insulin resistance syndrome (35–37). Interestingly,
one of these association studies reported that AdipoR2
polymorphisms were associated with decreased plasma
triglyceride levels (35). Another gene of interest in this
region of 12p is the wingless-type MMTV integration site
family, member 5B (WNT5B). An association study in a
Japanese population identiﬁed WNT5B as a new candidate
for conferring susceptibility to type 2 diabetes (38). Their
results suggest that the WNT5B gene plays an important
role in the regulation of adipocyte function and might
contribute to the pathogenesis of type 2 diabetes (38).
In conclusion, we found evidence for a major suscepti-
bility locus on chromosome 12p inﬂuencing plasma triglyc-
eride levels in Mexican Americans. The ﬁndings of the
present study, combined with the SNP association studies
performed in AdipoR2 (4,35), indicate that this locus
appears to have substantial inﬂuence on the phenotypic
variation in plasma triglyceride levels in Mexican Ameri-
cans. Further ﬁne-structure mapping will be required to
identify the remaining potential functional variants in this
region contributing to the linkage signal.
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